Overview
TerrAscend Q3 revenue of $65.1 mln missed analyst expectations
Company reports Q3 net loss from continuing operations of $9.9 mln
Completed $79 mln refinancing and had said it plans to exit Michigan market by year-end
Outlook
Company evaluating strategic M&A opportunities with a disciplined approach
TerrAscend aims to benefit from potential regulatory changes
Result Drivers
NORTHEAST MARKETS - Revenue stability supported by consistent performance in New Jersey, Maryland, and Pennsylvania
REFINANCING - Completed $79 mln non-dilutive refinancing of existing debt for strategic M&A
MARYLAND GROWTH - Maryland revenue increased 14.8% year-over-year with high gross margins
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$65.10 mln
$66.03 mln (4 Analysts)
Q3 EPS
Miss
-$0.08
-$0.02 (4 Analysts)
Q3 Gross Margin
52.10%
Q3 Net Income from Cont. Ops
-$9.90 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy"
Wall Street's median 12-month price target for Terrascend Corp is C$2.00, about 51.5% above its November 5 closing price of C$0.97
Press Release: ID:nGNX8g5F0K
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)